Background: HIV-ASSIST is a free, continuously updated, clinically validated online algorithm tool that synthesizes participant- and virus-specific characteristics and provides ART decision support based on the goals of maximizing viral suppression and tolerability. The aim of this study was to analyze the concordance of clinicians’ ART preferences with HIV-ASSIST recommendations and the influencing factors. Methods: We conducted a cross-sectional retrospective cohort study using electronic medical records of people with HIV (PWH) followed in the Infectious Diseases and Clinical Microbiology Department of Health Sciences University Izmir Tepecik Training and Research Hospital. The concordance between prescribed ART and HIV-ASSIST recommendations was evaluated. Results: The study included 101 participants (92 male, 91.1%), median age was 35 (20–67), and 24.8% of participants were treatment-experienced. The concordance between prescribed ART and HIV-ASSIST recommendations was 90.1% (absolute concordance 60.4%). The concordance rate was 89.5% (absolute concordance rate was 64.5%) in treatment-naive participants; 92% (absolute concordance rate was 48%) in treatment-experienced participants. Factors that were associated with discordance in the multivariate analysis were co-trimoxazole prophylaxis and hyperlipidemia. Conclusion: The recommendations of the HIV-ASSIST algorithm were found to be highly concordant with the ART prescriptions of our clinicians.
GokenginDTabakFKortenV, et al.The HIV treatment cascade in Turkey. HepHIV 2019 bucharest conference: challenges of timely and integrated testing and care. 2019, https://www.eurotest.org/media/usumqenv/po4_09.pdf
GandhiRTBedimoRHoyJF, et al.Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the international antiviral society–USA panel. JAMA2023; 329(1): 63–84. DOI: 10.1001/jama.2022.22246.
7.
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Washington, DC: Department of Health and Human Services, https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv (2023, Accessed 19 July 2023).
8.
Licensed products list. Turkish medicines and medical devices agency, republic of Turkey ministry of health, https://www.titck.gov.tr/dinamikmodul/85(2023, Accessed19 July 2023).
9.
AtalaySSönmezU. Digital twin in health care. In: KaraarslanEAydinÖCaliÜ, et al. (eds) Digital twin driven intelligent systems and emerging metaverse. Singapore: Springer, 2023, pp. 209–231. DOI: 10.1007/978-981-99-0252-1_10.
10.
WhicherDRappT. The value of artificial intelligence for healthcare decision making-lessons learned. Value Health2022; 25(3): 328–330. DOI: 10.1016/j.jval.2021.12.009.
11.
MaddaliMVMehtaniNJConverseC, et al.Development and validation of HIV-ASSIST, an online, educational, clinical decision support tool to guide patient-centered ARV regimen selection. J Acquir Immune Defic Syndr2019; 82(2): 188–194. DOI: 10.1097/QAI.0000000000002118.
12.
RamirezJAMaddaliMVBudakJZ, et al.Evaluating the concordance of clinician antiretroviral prescribing practices and HIV-ASSIST, an online clinical decision support tool. J Gen Intern Med2020; 35(5): 1498–1503. DOI: 10.1007/s11606-019-05531-4.
13.
European AIDS Clinical Society (EACS). Guidelines v 12.0. Guidelines for the Management of People Living with HIV in Europe. Brussels, Belgium: European AIDS Clinical Society, https://www.eacsociety.org/guidelines/eacs-guidelines (2023, Accessed 02 November 2023).
ThokalaPDevlinNMarshK, et al.Multiple criteria decision analysis for Health care decision making-an introduction: report 1 of the ISPOR MCDA emerging good practices task force. Value Health2016; 19(1–2): 1–13. DOI: 10.1016/j.jval.2015.12.003-016.
17.
Defining Adult Overweight & Obesity. Division of nutrition, physical activity, and obesity, national center for chronic disease prevention and Health promotion. https://www.cdc.gov/obesity/basics/adult-defining.html(2023, Accessed19 July 2023).
18.
GrundySMStoneNJBaileyAL, et al.2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation2019; 139: e1082–e1143. DOI: 10.1161/CIR.0000000000000625.
19.
KaraEİnkayaAÇAydın HaklıD, et al.Polypharmacy and drug-related problems among people living with HIV/AIDS: a single-center experience. Turk J Med Sci2019; 49(1): 222–229. DOI: 10.3906/sag-1807-295.
20.
KaraosmanoğluHKMeteBGündüzA, et al.Late presentation among patients with human immunodeficiency virus infection in Turkey. Cent Eur J Publ Health2019; 27(3): 229–234. DOI: 10.21101/cejph.a5416.
21.
ÖnalUAkalınH. Opportunistic infections among human immunodeficiency virus (HIV) infected participants in Turkey: a systematic review. Infect Dis Clin Microbiol2023; 2: 82–93. DOI: 10.36519/idcm.2023.214.
22.
TigenEGokenginDOzdemirHO, et al.Prevalence of cardiovascular disease (CVD) and comparison of risk category predictions of systemic coronary risk evaluation 2 (SCORE2) and four other CVD risk calculators among PLWHIV in Turkey. J Int AIDS Soc2022; 25: 134–135.
23.
KortenVGökenginDYıldırmakT, et al.Comparison of risk category predictions of framingham risk score (FRS), atherosclerotic cardiovascular disease risk score (ASCVD), systematic coronary risk evaluation (SCORE) and data collection on adverse events of anti-HIV drugs (D:A:D) in HIV infected patients. IDWeek2017; 4: S215.
24.
IvanyukALivioFBiollazJ, et al.Renal drug transporters and drug interactions. Clin Pharmacokinet2017; 56(8): 825–892. DOI: 10.1007/s40262-017-0506-8.
25.
RamirezJAMaddaliMVNematollahiS, et al.New strategies in clinical guideline delivery: randomized trial of online, interactive decision support versus guidelines for human immunodeficiency virus treatment selection by trainees. Clin Infect Dis2021; 72(9): 1608–1614. DOI: 10.1093/cid/ciaa299.
